Financings in Brief: Conceptus
This article was originally published in The Gray Sheet
Conceptus: IPO of 3 mil. shares is priced at $14 per share. Conceptus, which begins NASDAQ trading Feb. 1, was expecting to sell 2.5 mil. shares at $11 to $13 each ("The Gray Sheet" Jan. 8, p. 9)...
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.